ArticleBiomaterials2011
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.Human gene therapy · 2024Review
- Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.Journal of hematology & oncology · 2022Review
- MicroRNA-539-5p-Loaded PLGA Nanoparticles Grafted with iRGD as a Targeting Treatment for Choroidal Neovascularization.Pharmaceutics · 2022Article
- Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells.PloS one · 2022Article
- A NovelLife (Basel, Switzerland) · 2021Review
- Article
- Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs.Pharmaceutics · 2021Review
- Multifunctional Delivery Systems for Peptide Nucleic Acids.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Fluorescent tamoxifen-encapsulated nanocapsules functionalized with folic acid for enhanced drug delivery toward breast cancer cell line MCF-7 and cancer cell imaging.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.Yonsei medical journal · 2020Review
- Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities.The Yale journal of biology and medicine · 2017Review
- Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates.Scientific reports · 2017Article
- Engineering the RNA-Nanobio Interface.Bioengineering (Basel, Switzerland) · 2017Review
- Surface De-PEGylation Controls Nanoparticle-Mediated siRNA DeliveryTheranostics · 2017Article
- Crossing the barrier: treatment of brain tumors using nanochain particles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy.Technology · 2016Article
- Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization.Acta biomaterialia · 2016Article
- Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
We have developed a polymer nanoparticle-based siRNA delivery system that exploits a cell surface binding synergism between targeting ligands and cell-penetrating peptides. Nanoparticles were coated with folate and penetratin via a PEGylated phospholipid linker (DSPE-PEG): the combination of both of these ligands represents a strategy for enhancing intracellular delivery of attached polymer nanoparticles. Nanoparticles were characterized for size, morphology, density of surface modification, and ligand association and retention. The surface coverage achieved on DSPE-PEG-coated nanoparticles is as high as (or higher than) obtained with other ligand-modified nano-scale particulate systems (∼0.5-5 pmol ligand/cm²). Additionally, these nanoparticles were loaded with a high density of siRNA (∼130-140 pmol siRNA/mg nanoparticles), which is slowly released upon incubation in water. Synergies between the activity of surface binding and cell internalizing ligands on these siRNA-loaded nanoparticles impart delivery enhancements that improve their gene silencing efficacy both in culture and in tumor models. Traditionally, targeting ligands function by binding to cell surface receptors, while cell-penetrating peptides function by nonspecifically transporting across cell membranes. Interestingly, we have observed that improved delivery of these dual-functionalized nanoparticles was in part, a result of increased cell surface avidity afforded by both ligands. This siRNA delivery system presents an approach to surface modification of nanovehicles, in which multiple ligands function in parallel to enhance cell binding and uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.